Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 15, 2021 08:02 ET | Source: CoIMMUNE

CoImmune Announces Positive Results from Phase 1/2 Clinical Trial of Allogeneic CAR-CIK Cells in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia

Oral presentation at 63rd ASH Annual Meeting & Exposition shows that treatment based on company’s proprietary technology platform induced sustained responses without severe toxicities Company...
November 17, 2021 08:00 ET | Source: CoIMMUNE

CoImmune, Inc. Announces Research Collaboration with Yeda Research and Development Company Ltd.

DURHAM, N.C., Nov. 17, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, announced...
November 15, 2021 08:00 ET | Source: CoIMMUNE

CoImmune, Inc. Appoints Ed Baracchini, PhD, Chairman of the Board of Directors

DURHAM, N.C., Nov. 15, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today...
October 18, 2021 08:00 ET | Source: CoIMMUNE

CoImmune Announces Collaboration with Top US Cancer Center to Accelerate Development of CAR-CIK Therapies to Treat Solid Tumors

DURHAM, N.C., Oct. 18, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today...
September 20, 2021 09:38 ET | Source: CoIMMUNE

CoImmune, Inc. to Participate in Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

DURHAM, N.C., Sept. 20, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today...
July 06, 2021 09:16 ET | Source: CoIMMUNE

CoImmune, Inc. Appoints Michael Fekete and Greg Tibbitts to its Board of Directors

DURHAM, N.C., July 06, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class yet more affordable cellular...
February 24, 2021 09:00 ET | Source: CoIMMUNE

CoImmune, Inc. Announces Appointment of Ed Baracchini to Board of Directors

DURHAM, N.C., Feb. 24, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company developing cell-based therapeutics to treat unmet medical needs in blood-borne and solid...
December 16, 2020 14:27 ET | Source: CoIMMUNE

Chimeric antigen receptor (CAR)-modified cytokine induced killer cell (CAR-CIK) technology featured at ASH

DURHAM, N.C., Dec. 16, 2020 (GLOBE NEWSWIRE) -- CoImmune, Inc. today announced that its CAR-CIK technology was featured at the annual American Society of Hematology (ASH) meeting with an interim...
November 10, 2020 13:05 ET | Source: CoIMMUNE

CoImmune, Inc. Announces Closing of $45 Million Series A Financing

DURHAM, N.C., Nov. 10, 2020 (GLOBE NEWSWIRE) -- CoImmune, Inc., an immuno-oncology company developing cell-based therapeutics to treat unmet medical needs in blood-borne and solid tumor indications,...
April 30, 2020 15:55 ET | Source: CoIMMUNE

CoImmune, Inc., a US-Based Clinical-Stage Biotech, Completes Merger with Formula Pharmaceuticals, Inc.

DURHAM, N.C. , April 30, 2020 (GLOBE NEWSWIRE) -- CoImmune, Inc. today announced that it has successfully completed the merger with Formula Pharmaceuticals, Inc., bringing together two therapeutic...